These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Transglutaminase 2-targeted autoantibodies in celiac disease: Pathogenetic players in addition to diagnostic tools? Lindfors K; Mäki M; Kaukinen K Autoimmun Rev; 2010 Sep; 9(11):744-9. PubMed ID: 20547248 [TBL] [Abstract][Full Text] [Related]
4. Secretion of celiac disease autoantibodies after in vitro gliadin challenge is dependent on small-bowel mucosal transglutaminase 2-specific IgA deposits. Stenman SM; Lindfors K; Korponay-Szabo IR; Lohi O; Saavalainen P; Partanen J; Haimila K; Wieser H; Mäki M; Kaukinen K BMC Immunol; 2008 Feb; 9():6. PubMed ID: 18312620 [TBL] [Abstract][Full Text] [Related]
5. Anti-type 2 transglutaminase antibodies as modulators of type 2 transglutaminase functions: a possible pathological role in celiac disease. Martucciello S; Paolella G; Esposito C; Lepretti M; Caputo I Cell Mol Life Sci; 2018 Nov; 75(22):4107-4124. PubMed ID: 30136165 [TBL] [Abstract][Full Text] [Related]
6. Deamidated gliadin peptides form epitopes that transglutaminase antibodies recognize. Korponay-Szabó IR; Vecsei Z; Király R; Dahlbom I; Chirdo F; Nemes E; Fésüs L; Mäki M J Pediatr Gastroenterol Nutr; 2008 Mar; 46(3):253-61. PubMed ID: 18376241 [TBL] [Abstract][Full Text] [Related]
7. Immunoglobulin A anti-tissue transglutaminase antibody deposits in the small intestinal mucosa of children with no villous atrophy. Tosco A; Maglio M; Paparo F; Rapacciuolo L; Sannino A; Miele E; Barone MV; Auricchio R; Troncone R J Pediatr Gastroenterol Nutr; 2008 Sep; 47(3):293-8. PubMed ID: 18728524 [TBL] [Abstract][Full Text] [Related]
8. Celiac anti-type 2 transglutaminase antibodies induce differential effects in fibroblasts from celiac disease patients and from healthy subjects. Paolella G; Lepretti M; Barone MV; Nanayakkara M; Di Zenzo M; Sblattero D; Auricchio S; Esposito C; Caputo I Amino Acids; 2017 Mar; 49(3):541-550. PubMed ID: 27613408 [TBL] [Abstract][Full Text] [Related]
9. Autoantibodies from patients with celiac disease inhibit transglutaminase 2 binding to heparin/heparan sulfate and interfere with intestinal epithelial cell adhesion. Teesalu K; Panarina M; Uibo O; Uibo R; Utt M Amino Acids; 2012 Feb; 42(2-3):1055-64. PubMed ID: 21847613 [TBL] [Abstract][Full Text] [Related]
10. Transamidation of wheat flour inhibits the response to gliadin of intestinal T cells in celiac disease. Gianfrani C; Siciliano RA; Facchiano AM; Camarca A; Mazzeo MF; Costantini S; Salvati VM; Maurano F; Mazzarella G; Iaquinto G; Bergamo P; Rossi M Gastroenterology; 2007 Sep; 133(3):780-9. PubMed ID: 17678925 [TBL] [Abstract][Full Text] [Related]
11. Early developing celiac disease in children with cerebral palsy. Stenberg R; Kaukinen K; Bengtsson M; Lindberg E; Dahle C J Pediatr Gastroenterol Nutr; 2011 Dec; 53(6):674-8. PubMed ID: 21697743 [TBL] [Abstract][Full Text] [Related]
12. A quantitative analysis of transglutaminase 2-mediated deamidation of gluten peptides: implications for the T-cell response in celiac disease. Dørum S; Qiao SW; Sollid LM; Fleckenstein B J Proteome Res; 2009 Apr; 8(4):1748-55. PubMed ID: 19239248 [TBL] [Abstract][Full Text] [Related]
16. Are transglutaminase 2 inhibitors able to reduce gliadin-induced toxicity related to celiac disease? A proof-of-concept study. Rauhavirta T; Oittinen M; Kivistö R; Männistö PT; Garcia-Horsman JA; Wang Z; Griffin M; Mäki M; Kaukinen K; Lindfors K J Clin Immunol; 2013 Jan; 33(1):134-42. PubMed ID: 22878839 [TBL] [Abstract][Full Text] [Related]